- Home
- ESPR vs EOD Comparison
ESPR vs EOD Comparison
Compare ESPR & EOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- EOD
- Stock Information
- Founded
- ESPR 2008
- EOD 2007
- Country
- ESPR United States
- EOD United States
- Employees
- ESPR N/A
- EOD N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- EOD Investment Managers
- Sector
- ESPR Health Care
- EOD Finance
- Exchange
- ESPR Nasdaq
- EOD Nasdaq
- Market Cap
- ESPR 202.2M
- EOD 232.1M
- IPO Year
- ESPR 2013
- EOD N/A
- Fundamental
- Price
- ESPR $1.20
- EOD $5.44
- Analyst Decision
- ESPR Buy
- EOD
- Analyst Count
- ESPR 6
- EOD 0
- Target Price
- ESPR $6.50
- EOD N/A
- AVG Volume (30 Days)
- ESPR 3.1M
- EOD 118.1K
- Earning Date
- ESPR 08-11-2025
- EOD 01-01-0001
- Dividend Yield
- ESPR N/A
- EOD 9.28%
- EPS Growth
- ESPR N/A
- EOD N/A
- EPS
- ESPR N/A
- EOD N/A
- Revenue
- ESPR $259,574,000.00
- EOD N/A
- Revenue This Year
- ESPR $4.07
- EOD N/A
- Revenue Next Year
- ESPR N/A
- EOD N/A
- P/E Ratio
- ESPR N/A
- EOD N/A
- Revenue Growth
- ESPR 12.99
- EOD N/A
- 52 Week Low
- ESPR $0.69
- EOD $3.73
- 52 Week High
- ESPR $3.94
- EOD $4.71
- Technical
- Relative Strength Index (RSI)
- ESPR 63.86
- EOD 68.50
- Support Level
- ESPR $1.10
- EOD $5.36
- Resistance Level
- ESPR $1.26
- EOD $5.26
- Average True Range (ATR)
- ESPR 0.08
- EOD 0.06
- MACD
- ESPR 0.02
- EOD 0.01
- Stochastic Oscillator
- ESPR 93.55
- EOD 97.30
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.